Germany's JenaValve Technology, maker of a CE-marked transcatheter aortic valve replacement, just announced that it has received $26.5 million in expanded Series C financing co-led by entrepreneur Rudi Mariën and investment firm Valiance, as it seeks to join Medtronic and Edwards Lifesciences in the U.S. market.
Sanofi is expanding its relationship with close partner Evotec, signing a deal worth up to $330 million to collaborate on cell-replacement therapies for diabetes.
The National Cancer Institute awarded a grant of $2.6 million to fund a clinical trial of Lightpoint Medical's molecular imaging technology to diagnose lymph node and gynecological cancers.
As patient monitoring picks up steam in the med tech industry, global technology organization IEEE is rolling out a new standard for operating devices geared toward the diabetes market.
Irish CRO Icon has signed on to be the exclusive service provider for a new U.K. biotech startup, planning to help the nascent company advance a trio of Novartis-developed drugs.
Robotic surgery can allow greater surgical precision but does have some risks stemming mostly from inadequate physician training. Now, a startup is moving into the clinic with a device that shifts robotic surgery from a typical large, fixed, external surgical system to a device that actually is inserted into the body through a small incision in the navel.
MIT's Daniel Anderson recently discussed the future of beta cell replacement technology with Dr. Gordon Weir of Harvard Medical School. Their research has applications to the development of an artificial pancreas.
Johnson & Johnson's Animas is working with Type 1 diabetes technology nonprofit Tidepool to use its open-source software platform to assemble and analyze data for diabetes device, fitness and food tracking. The news comes in the wake of announcements in recent months from major diabetes device makers, including Medtronic, DexCom and Insulet, that they are partnering with startup Glooko to similarly enable connectivity as well as data transmission and analysis.
Pennsylvania drugmaker Zynerba Pharmaceuticals is making its way to Wall Street with some cannabis-derived treatments for central nervous system disorders, raising $42 million in an IPO.
A California judge has stepped between two top research institutions fighting over a vast Alzheimer's disease R&D program with ties to Big Pharma, ordering the study's new managers to hand it back for the time being.